Market Research Reports and Industry Reports

Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates. Changing political scenario in Japan will accelerate the pace of reforms in Japan as recently; the Liberal Democratic Party (LDP) of Japan came back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with a focus on curbing healthcare costs by means of enhancing generic drugs penetration. Our report discusses in details about the implications of these changes on Innovator and generic domestic Japanese pharma companies.

Global companies on the other hand are going to see a favorable scenario in coming years - expected launches in 2013-2014 from global companies will increase competition to domestic players mainly in the respiratory, oncology and rheumatoid arthritis therapy areas, and will increase overall market size of Diabetes and Osteoporosis markets.

Going forward, for 2013 Generic companies will continue to witness a growth story, we think that the recent incentives to promote generic uptake have played out well and at current levels, we do not see meaningful growth until early 2014 when new set of incentives will start playing off. However, in the related space drug chain stores and biogenerics are two new arenas which we see as next growth drivers we have analyzed these two novel spaces as well in this report.
Report Card 2012 (Japan Pharma Stock Performance Hit & Miss)
2. Japan Pharma Valuation
3. Large Pharma - Rich Pipeline
4. Key Pipeline Candidates- Japan Pharma
5. Global Companies Expected Major Launches In Japan- 2013/14
6. Consolidation Activities Major M&A In Japan - Last 5 Years
7. Japanese Global Cos Overseas Sales
8. JP Companies Performance Vs. US/EU
9. Reforms In 2012 And Implications
10. Revised Incentives For Pharmacies
11. Looming Generic Opportunity
12. Key Generic Companies: Sales Break Up
13. Generic Companies: Relative Standing
14. Japan Generic: Segments
15. Drug Chain Stores: Profitability Trend
16. Biogenerics Opportunities In Japan
17. Daiichi Sankyo: Datablock
18. Daiichi Sankyo: Sum Of Parts
19. Daiichi Sankyo: Key Milestones
20. Daiichi Sankyo: Relative Clinical Profile Of Xarelto, Eliquis And Edoxaban
In SPAF
21. Daiichi Sankyo: Different Geographies
22. Daiichi Sankyo: Edoxaban PhII Clinical Study In SPAF: Global; Japan;
Taiwan
23. Daiichi Sankyo: Baseline Characteristics Comparison Of Pivotal Trials In
SPAF
Outlook 2013: Japan Pharma Table of Contents / 5
MPAdvisors
24. Daiichi Sankyo: Comparison Of Available Osteoporosis Treatments
25. Daiichi Sankyo: Ranmark (Denosumab) - Development Status In Japan
26. Daiichi Sankyo: Comparison Between Zometa And Denosumab In
Oncology
27. Daiichi Sankyo: RBXY: Datablock
28. Daiichi Sankyo: Daiichi Sankyo Espha Approvals
29. Kyorin - Datablock
30. Kyorin -Key Milestones
31. Kyorin -KRP-108: Relating Composition
32. Kyorin -Kipres: Competitive Landscape In Japan
33. Kyorin - Japanese OBS Market
34. Mitsubishi Tanabe - Datablock
35. Mitsubishi Tanabe - Key Milestones
36. Mitsubishi Tanabe SGLT2 Pipeline (Japan And Global Status)
37. Mitsubishi Tanabe SGLT2 Inhibitors- Clinical Data Comparison
38. Mitsubishi Tanabe - Key Products
39. Mitsubishi Tanabe - Japan RA Market
40. Mitsubishi Tanabe - HCV Pipeline (Japan)
41. Mitsubishi Tanabe - Marketed DPP4 In Japan
42. Mitsubishi Tanabe - DPP4 Pipeline* (Japan And Global Status)
43. Mitsubishi Tanabe - Avanafil : Relative Positioning
44. Mitsubishi Tanabe - Dividend Estimates
45. Mitsubishi Tanabe - Key Pipeline Candidates
46. Shionogi - Datablock
47. Shionogi - Key Milestones
48. Shionogi - Single Trial Data
49. Shionogi - Dolutegravir PhIII Trials
50. Shionogi - HIV Marketed Drugs
51. Shionogi - HIV Pipeline Drugs
52. Shionogi - Spring-2 Trial Data
53. Shionogi - Dolutegravir NPV- Shionogi
54. Eisai - Datablock
55. Eisai - Key Milestones
56. Eisai - Key Pipeline Candidates
57. Eisai - Aricept WW Sales Projections
58. Eisai - Aricept Sales In Japan: Strength Wise
59. Eisai - Halaven A Number Of Indications Underway
60. Eisai - Upcoming Competitors For Halaven
61. Eisai - Fycompa Clinical Data
62. Eisai - Data Presented At IEC Annual Meeting 2011
63. Eisai - Eritoran Vs. Xigris: Comparative Efficacy
64. Astellas - Datablock
65. Astellas - Key Milestones
66. Astellas - Long-Term PhI/II Follow-Up Results
67. Astellas - Overactive Bladder Syndrome: Key Drugs
68. Astellas - Mirabegron Efficacy And Tolerability Results In European And
Outlook 2013: Japan Pharma Table of Contents / 6
MPAdvisors
Australian Patients
69. Astellas - Mirabegron Efficacy And Tolerability Results In North American
Patients
70. Astellas - Competitive Landscape: Advanced Renal Cell Carcinoma
71. Astellas - Select Oral Ra/Psoriasis Drugs In Development
72. Chugai - Datablock
73. Chugai - Key Milestones
74. Chugai - Actemra - Ongoing Global Trials
75. Chugai - Japan RA Market
76. Chugai - Efficacy And Safety Comparison Of TDM1 Vs.
Trastuzumab+Docetaxel In First Line BC TDM1: Ongoing Important
Clinical Studies Of T-DM1 In Late Stage Her 2 Positive Breast Cancer
77. Chugai - Chugai-Sales Break Up
78. Dainippon Sumitomo - Datablock
79. Dainippon Sumitomo - Key Milestones
80. Dainippon Sumitomo - Psychiatrists See High Unmet Need
81. Dainippon Sumitomo - Lurasidone - Ongoing/Planned Clinical Studies
82. Dainippon Sumitomo - Pearl 2 Data
83. Dainippon Sumitomo - Pearl 3 Vs. Seroquel: Overall- A Good Risk/Benefit
Ratio
84. Dainippon Sumitomo - Latuda SWOT Analysis
85. Dainippon Sumitomo - Pearl 3 Extension Study Data- Non Inferior To
Seroquel XR
86. Dainippon Sumitomo - Dainippon Sumitomo-Key Pipeline Candidates
87. KHK - Datablock
88. KHK - Key Milestones
89. KHK -Potelligent Technology
90. KHK -Segment Classification
91. KHK -Income Statement
92. KHK -Pharma Sales Trend
93. Nippon Chemiphar - Datablock
94. Nippon Chemiphar - Entry Of Foreign Companies In Japan Generic
Market
95. Nippon Chemiphar - Generic Companies: Relative Valuation
96. Sawai - Datablock
97. Sawai - Excellent Reach In Various Markets
98. Sawai - Reforms In 2012 And Implications
99. Sawai - Sawai Vs. Key Competitors Sales Break Up Key
100. Sawai - Generic Companies: Relative Valuation
101. Sawai - Foreign Companies Entry In Japan Generic Market
102. Takeda -Datablock
103. Takeda -Antidepressants Ww Competitive Landscape
104. Takeda -PhIII Data Summary- Vortioxetine
105. Takeda -Antidepressants: Key Pipeline Candidates And
Issues
106. Takeda -Antidepressants Market In Japan
107. Takeda -Key Attributes Of Major Anti-Diabetic Drugs
108. Takeda -Advantage, Disadvantage Of Key Anti-Diabetic
109. Drugs
Outlook 2013: Japan Pharma Table of Contents / 7
MPAdvisors
110. Takeda -Ongoing Clinical Trials Of Tak-875
111. Takeda -Tak-875 Ph II Trial Design
112. Datablock
113. Reforms In 2012 And Implications
114. Towa Vs. Key Competitors Sales Break Up Key
115. Foreign Companies Entry In Japan Generic Market
116. Revenue Growth Of Generic Cos. In Price Cut Years
Annexures
1. Key Milestones- Japan Pharma
2. Japan Generic Market Model
3. Top 25 Products Vs. Generic Threat
4. Daiichi Sankyo - Domestic Pharma Sales Trend
5. Mitsubishi Tanabe - Long Listed Product Sales As % Of Total Domestic
Sales
6. Shionogi - Viking- PhII Findings
7. Shionogi - Spring- PhIII Findings
8. Shionogi - Single- PhIII Findings
9. Shionogi - Dolutegravir PhIII Program
10. Eisai - Consolidated Income Statement: MPe Vs. Hayabusa
11. Eisai - Domestic Pharma Sales
12. Eisai - Belviq Cost To Eisai
13. Astellas - Xtandi: NPV Shrinks Due To Commercialization Agreement
14. Chugai - Possibilities Of Roche Increasing Its Stake In Chugai Are Real &
High
15. Chugai - Roche-Chugai: Maturing Relationship Timeline
16. Chugai - Potential Benefits To Roche By Increasing Stake In Chugai
17. Chugai - Widening Prospects Of Actemra
18. Chugai - Domestic Japan Pharma Sales
19. Dainippon Sumitomo Dainippon Sumitomo- Key Pipeline Candidates
20. Dainippon Sumitomo - Dainippon Sumitomo-Key Pipeline Candidates
21. Sawai - Generic Companies: Relative Standing
22. Takeda - Key Pipeline Candidates

List Of Tables

N/A

List Of Figures

Report Card 2012 (Japan Pharma Stock Performance Hit & Miss)
2. Japan Pharma Valuation
3. Large Pharma - Rich Pipeline
4. Key Pipeline Candidates- Japan Pharma
5. Global Companies Expected Major Launches In Japan- 2013/14
6. Consolidation Activities Major M&A In Japan - Last 5 Years
7. Japanese Global Cos Overseas Sales
8. JP Companies Performance Vs. US/EU
9. Reforms In 2012 And Implications
10. Revised Incentives For Pharmacies
11. Looming Generic Opportunity
12. Key Generic Companies: Sales Break Up
13. Generic Companies: Relative Standing
14. Japan Generic: Segments
15. Drug Chain Stores: Profitability Trend
16. Biogenerics Opportunities In Japan
17. Daiichi Sankyo: Datablock
18. Daiichi Sankyo: Sum Of Parts
19. Daiichi Sankyo: Key Milestones
20. Daiichi Sankyo: Relative Clinical Profile Of Xarelto, Eliquis And Edoxaban
In SPAF
21. Daiichi Sankyo: Different Geographies
22. Daiichi Sankyo: Edoxaban PhII Clinical Study In SPAF: Global; Japan;
Taiwan
23. Daiichi Sankyo: Baseline Characteristics Comparison Of Pivotal Trials In
SPAF
Outlook 2013: Japan Pharma Table of Contents / 5
MPAdvisors
24. Daiichi Sankyo: Comparison Of Available Osteoporosis Treatments
25. Daiichi Sankyo: Ranmark (Denosumab) - Development Status In Japan
26. Daiichi Sankyo: Comparison Between Zometa And Denosumab In
Oncology
27. Daiichi Sankyo: RBXY: Datablock
28. Daiichi Sankyo: Daiichi Sankyo Espha Approvals
29. Kyorin - Datablock
30. Kyorin -Key Milestones
31. Kyorin -KRP-108: Relating Composition
32. Kyorin -Kipres: Competitive Landscape In Japan
33. Kyorin - Japanese OBS Market
34. Mitsubishi Tanabe - Datablock
35. Mitsubishi Tanabe - Key Milestones
36. Mitsubishi Tanabe SGLT2 Pipeline (Japan And Global Status)
37. Mitsubishi Tanabe SGLT2 Inhibitors- Clinical Data Comparison
38. Mitsubishi Tanabe - Key Products
39. Mitsubishi Tanabe - Japan RA Market
40. Mitsubishi Tanabe - HCV Pipeline (Japan)
41. Mitsubishi Tanabe - Marketed DPP4 In Japan
42. Mitsubishi Tanabe - DPP4 Pipeline* (Japan And Global Status)
43. Mitsubishi Tanabe - Avanafil : Relative Positioning
44. Mitsubishi Tanabe - Dividend Estimates
45. Mitsubishi Tanabe - Key Pipeline Candidates
46. Shionogi - Datablock
47. Shionogi - Key Milestones
48. Shionogi - Single Trial Data
49. Shionogi - Dolutegravir PhIII Trials
50. Shionogi - HIV Marketed Drugs
51. Shionogi - HIV Pipeline Drugs
52. Shionogi - Spring-2 Trial Data
53. Shionogi - Dolutegravir NPV- Shionogi
54. Eisai - Datablock
55. Eisai - Key Milestones
56. Eisai - Key Pipeline Candidates
57. Eisai - Aricept WW Sales Projections
58. Eisai - Aricept Sales In Japan: Strength Wise
59. Eisai - Halaven A Number Of Indications Underway
60. Eisai - Upcoming Competitors For Halaven
61. Eisai - Fycompa Clinical Data
62. Eisai - Data Presented At IEC Annual Meeting 2011
63. Eisai - Eritoran Vs. Xigris: Comparative Efficacy
64. Astellas - Datablock
65. Astellas - Key Milestones
66. Astellas - Long-Term PhI/II Follow-Up Results
67. Astellas - Overactive Bladder Syndrome: Key Drugs
68. Astellas - Mirabegron Efficacy And Tolerability Results In European And
Outlook 2013: Japan Pharma Table of Contents / 6
MPAdvisors
Australian Patients
69. Astellas - Mirabegron Efficacy And Tolerability Results In North American
Patients
70. Astellas - Competitive Landscape: Advanced Renal Cell Carcinoma
71. Astellas - Select Oral Ra/Psoriasis Drugs In Development
72. Chugai - Datablock
73. Chugai - Key Milestones
74. Chugai - Actemra - Ongoing Global Trials
75. Chugai - Japan RA Market
76. Chugai - Efficacy And Safety Comparison Of TDM1 Vs.
Trastuzumab+Docetaxel In First Line BC TDM1: Ongoing Important
Clinical Studies Of T-DM1 In Late Stage Her 2 Positive Breast Cancer
77. Chugai - Chugai-Sales Break Up
78. Dainippon Sumitomo - Datablock
79. Dainippon Sumitomo - Key Milestones
80. Dainippon Sumitomo - Psychiatrists See High Unmet Need
81. Dainippon Sumitomo - Lurasidone - Ongoing/Planned Clinical Studies
82. Dainippon Sumitomo - Pearl 2 Data
83. Dainippon Sumitomo - Pearl 3 Vs. Seroquel: Overall- A Good Risk/Benefit
Ratio
84. Dainippon Sumitomo - Latuda SWOT Analysis
85. Dainippon Sumitomo - Pearl 3 Extension Study Data- Non Inferior To
Seroquel XR
86. Dainippon Sumitomo - Dainippon Sumitomo-Key Pipeline Candidates
87. KHK - Datablock
88. KHK - Key Milestones
89. KHK -Potelligent Technology
90. KHK -Segment Classification
91. KHK -Income Statement
92. KHK -Pharma Sales Trend
93. Nippon Chemiphar - Datablock
94. Nippon Chemiphar - Entry Of Foreign Companies In Japan Generic
Market
95. Nippon Chemiphar - Generic Companies: Relative Valuation
96. Sawai - Datablock
97. Sawai - Excellent Reach In Various Markets
98. Sawai - Reforms In 2012 And Implications
99. Sawai - Sawai Vs. Key Competitors Sales Break Up Key
100. Sawai - Generic Companies: Relative Valuation
101. Sawai - Foreign Companies Entry In Japan Generic Market
102. Takeda -Datablock
103. Takeda -Antidepressants Ww Competitive Landscape
104. Takeda -PhIII Data Summary- Vortioxetine
105. Takeda -Antidepressants: Key Pipeline Candidates And
Issues
106. Takeda -Antidepressants Market In Japan
107. Takeda -Key Attributes Of Major Anti-Diabetic Drugs
108. Takeda -Advantage, Disadvantage Of Key Anti-Diabetic
109. Drugs
Outlook 2013: Japan Pharma Table of Contents / 7
MPAdvisors
110. Takeda -Ongoing Clinical Trials Of Tak-875
111. Takeda -Tak-875 Ph II Trial Design
112. Datablock
113. Reforms In 2012 And Implications
114. Towa Vs. Key Competitors Sales Break Up Key
115. Foreign Companies Entry In Japan Generic Market
116. Revenue Growth Of Generic Cos. In Price Cut Years
Annexures
1. Key Milestones- Japan Pharma
2. Japan Generic Market Model
3. Top 25 Products Vs. Generic Threat
4. Daiichi Sankyo - Domestic Pharma Sales Trend
5. Mitsubishi Tanabe - Long Listed Product Sales As % Of Total Domestic
Sales
6. Shionogi - Viking- PhII Findings
7. Shionogi - Spring- PhIII Findings
8. Shionogi - Single- PhIII Findings
9. Shionogi - Dolutegravir PhIII Program
10. Eisai - Consolidated Income Statement: MPe Vs. Hayabusa
11. Eisai - Domestic Pharma Sales
12. Eisai - Belviq Cost To Eisai
13. Astellas - Xtandi: NPV Shrinks Due To Commercialization Agreement
14. Chugai - Possibilities Of Roche Increasing Its Stake In Chugai Are Real &
High
15. Chugai - Roche-Chugai: Maturing Relationship Timeline
16. Chugai - Potential Benefits To Roche By Increasing Stake In Chugai
17. Chugai - Widening Prospects Of Actemra
18. Chugai - Domestic Japan Pharma Sales
19. Dainippon Sumitomo Dainippon Sumitomo- Key Pipeline Candidates
20. Dainippon Sumitomo - Dainippon Sumitomo-Key Pipeline Candidates
21. Sawai - Generic Companies: Relative Standing
22. Takeda - Key Pipeline Candidates

Hinduja Global Solutions Ltd Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Hinduja Global Solutions Ltd Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions,

USD 200View Report

HanmiGlobal Co., Ltd Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

HanmiGlobal Co., Ltd Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT

USD 200View Report

H&H global resource Co., Ltd Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

H&H global resource Co., Ltd Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market

USD 200View Report

Global Pharmaceuticals-Gel Sales Market Report 2016

Notes:Sales, means the sales volume of Pharmaceuticals-GelRevenue, means the sales value of Pharmaceuticals-GelThis report studies sales (consumption) of Pharmaceuticals-Gel in Global market, especially in United States, China, Europe, Japan, focuses

USD 4000View Report

Global Pharmaceutical Contract Manufacturing Sales Market Report 2016

Notes:Sales, means the sales volume of Pharmaceutical Contract ManufacturingRevenue, means the sales value of Pharmaceutical Contract ManufacturingThis report studies sales (consumption) of Pharmaceutical Contract Manufacturing in Global market, especially in

USD 4000View Report

Global Pharmaceutical Fermenter Market Research Report 2016

Notes:Production, means the output of Pharmaceutical FermenterRevenue, means the sales value of Pharmaceutical FermenterThis report studies Pharmaceutical Fermenter in Global market, especially in North America, Europe, China, Japan, Southeast Asia

USD 2900View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2500
  • Site Licence    $ 5000
  • Enterprisewide Licence    $ 7500
$ 2500

Reports Details

Published Date : Jan 2013
No. of Pages :146
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment